Send me real-time posts from this site at my email
Zacks

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

AxoGen (AXGN) shares soared 8.6% in the last trading session to close at $12.25. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks.

Axogen scored a strong price rise on investors’ optimism surrounding the company’s participation in the 77th Annual Meeting of the American Society for Surgery of the Hand (ASSH). During the conference Axogen will host an industry forum symposium entitled Late-Breaking, State-of-the-Art Nerve Reconstruction Data: The How and Why of Implementing this New Data into Your Clinical Practice.

Further, the company has also benefitted from a solid boost in the U.S. equity market yesterday. At the close on Sep 28, 2022, the Dow Jones Industrial Average was up 1.88%. The S&P 500 index as well as the NASDAQ Composite index climbed 1.97% and 2.05% respectively.

This regenerative medicine company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -66.7%. Revenues are expected to be $36.1 million, up 15.7% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For AxoGen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AXGN going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

AxoGen is a member of the Zacks Medical - Instruments industry. One other stock in the same industry, Asensus Surgical ASXC, finished the last trading session 5.5% higher at $0.44. ASXC has returned -23.7% over the past month.

Asensus Surgical's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. Compared to the company's year-ago EPS, this represents a change of -16.7%. Asensus Surgical currently boasts a Zacks Rank of #2 (Buy).


FREE Report: The Metaverse is Exploding! Don’t You Want to Cash In?

Rising gas prices. The war in Ukraine. America's recession. Inflation. It's no wonder why the metaverse is so popular and growing every day. Becoming Spider Man and fighting Darth Vader is infinitely more appealing than spending over $5 per gallon at the pump. And that appeal is why the metaverse can provide such massive gains for investors. But do you know where to look? Do you know which metaverse stocks to buy and which to avoid? In a new FREE report from Zacks' leading stock specialist, we reveal how you could profit from the internet’s next evolution. Even though the popularity of the metaverse is spreading like wildfire, investors like you can still get in on the ground floor and cash in. Don't miss your chance to get your piece of this innovative $30 trillion opportunity - FREE.

>>Yes, I want to know the top metaverse stocks for 2022>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AxoGen, Inc. (AXGN): Free Stock Analysis Report
 
Asensus Surgical, Inc. (ASXC): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue